These are top 10 stocks traded on the Robinhood UK platform in July
BOSTON - Volta Labs, a genomics applications company, has integrated its Callisto™ Sample Prep System into Ginkgo Bioworks’ Illumina (NASDAQ:ILMN) sequencing workflow, aiming to streamline and automate complex processes in genomics research. Ginkgo Bioworks, listed on the NYSE under the ticker DNA, is recognized for its cell programming and biosecurity platform. According to InvestingPro data, the company’s stock has shown strong momentum with a 23% return over the past six months, despite recent market volatility.
The Callisto system is designed to handle the variability in batch sizes that Ginkgo Bioworks encounters during its short-read sequencing workflow, which involves pooling thousands of individual samples. Alex Plocik, Senior Director of Genomics at Ginkgo, highlighted the system’s ability to reduce operating costs and provide access to multiple sequencing technologies on a single platform. This focus on cost efficiency comes at a crucial time, as InvestingPro analysis shows the company maintaining a strong liquidity position with a current ratio of 5.79, though it faces challenges with rapid cash burn.
Udayan Umapathi, founder and CEO of Volta Labs, expressed enthusiasm for the partnership with Ginkgo Bioworks, noting their instrumental role in refining Volta’s solutions for high throughput laboratories. He anticipates the short-term benefits of integrating Callisto into Illumina workflows and the long-term potential for broader applications.
The Callisto system leverages advanced technologies such as electrowetting, magnetic and acoustic capabilities, and proprietary VoltaNode™ technology. These innovations enable precise liquid separation, efficient DNA elution from beads, and flexibility in batch processing. Volta Labs has also released a new app for size selection, which is pivotal for labs performing sequencing on Illumina and other platforms, to purify and select optimal fragment sizes for sequencing.
Volta Labs aims to transform biological research and analysis by improving performance and scalability in sample preparation, thus allowing scientists to concentrate on advancing biological research.
Ginkgo Bioworks is known for its comprehensive cell programming services across various markets, including food, agriculture, pharmaceuticals, and industrial chemicals. The company’s biosecurity division is developing infrastructure and technologies to address biological threats. With revenue of $218 million in the last twelve months and an impressive gross profit margin of 81%, the company shows potential despite current challenges. Investors should note that Ginkgo’s next earnings report is scheduled for February 28, 2025. For deeper insights into DNA’s financial health and growth prospects, explore the comprehensive analysis available on InvestingPro, which offers exclusive access to over 10 additional ProTips and detailed financial metrics.
This integration is based on a press release statement and reflects the latest advancements in genomics research automation by Volta Labs and Ginkgo Bioworks.
In other recent news, Ginkgo Bioworks has entered into a collaboration with Carnegie Mellon University to develop bioelectronic devices aimed at diagnosing and treating hormone disorders. This project is funded by a subcontract worth up to $9.4 million from the Advanced Research Projects Agency for Health’s Resilient Extended Automatic Cell Therapies program. The initiative, known as the Biointegrated Implantable Systems for Cell-based Sensing and Therapy, focuses on creating implantable devices that use engineered cells to manage chronic diseases such as thyroid disorders, diabetes, and obesity. These devices are designed to function for at least one year after implantation, allowing patients and healthcare providers to monitor and control treatment remotely via a smartphone. Jesse Dill from Ginkgo Bioworks expressed optimism about the project’s potential to provide innovative solutions for chronic disease management. Mike Nehil highlighted the company’s expertise in mammalian cell engineering as a significant asset to this academic-led effort. The partnership underscores Ginkgo’s dedication to addressing complex health challenges through collaboration with academic institutions and funding agencies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.